Monoclonal antibody immunotherapy that binds and blocks LAIR-1 (CD305), antagonizing collagen/C1q-triggered ITIM signaling via SHP-1/2 to relieve immune suppression and potentially directly target LAIR-1–expressing leukemic blasts and stem/progenitor cells.
Humanized IgG1k monoclonal antibody that binds and blocks LAIR‑1 (CD305), antagonizing collagen/C1q-triggered ITIM signaling via SHP‑1/2 to relieve immune suppression; additionally leverages Fc effector functions (ADCC/ADCP) to deplete LAIR‑1–expressing AML leukemic stem and blast cells, reducing survival and proliferation.
Anti–LAIR-1 IgG1 binds LAIR-1 on target cells and engages FcγR-expressing effectors to mediate ADCC (NK cells) and ADCP (macrophages); blockade of LAIR-1 inhibitory signaling also reduces survival of LAIR-1–positive AML blasts/LSCs.
Naxitamab, a humanized IgG1 anti-GD2 monoclonal antibody that binds GD2 on neuroblastoma cells and mediates ADCC and complement-dependent cytotoxicity.
Humanized IgG1 monoclonal antibody targeting the tumor-associated ganglioside GD2; binding to GD2 on neuroblastoma cells recruits immune effector functions to kill tumor cells via antibody‑dependent cell‑mediated cytotoxicity (ADCC) through FcγR‑bearing cells (e.g., NK cells, macrophages, granulocytes) and complement‑dependent cytotoxicity (CDC). No cytotoxic payload.
Anti-GD2 IgG1 binds GD2 on tumor cells and triggers FcγR-mediated ADCC by NK cells/macrophages/granulocytes and complement-dependent cytotoxicity, leading to target-cell lysis.
Humanized anti-CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis.
Humanized anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20+ B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis, leading to immunosuppression.
Anti-CD20 mAb binds CD20 on B cells and triggers complement-dependent cytotoxicity and Fc-mediated ADCC by NK cells/macrophages; can also induce apoptosis of CD20+ cells.
Fully human anti-CD20 monoclonal antibody (subcutaneous) that depletes B cells.
Fully human anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes them via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity/phagocytosis, reducing CD20+ B-cell populations.
Ofatumumab binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC/ADCP by immune effector cells, leading to lysis and clearance of CD20+ cells.
Allogeneic anti-CD19 CAR-T cell therapy that redirects donor T cells to CD19 on B-lineage blasts to induce T-cell–mediated cytotoxicity.
Allogeneic donor T cells engineered with an anti-CD19 chimeric antigen receptor bind CD19 on B-lineage blasts and induce T cell–mediated cytotoxicity; elimination of TCR/CD3 expression reduces graft-versus-host disease risk.
Anti-CD19 CAR T cells bind CD19 on target cells and induce T cell–mediated killing via perforin/granzyme release and death-receptor pathways.